Search

Your search keyword '"Bollas A"' showing total 1,105 results
Start Over Author "Bollas A"
1,105 results on '"Bollas A"'

3. Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia

Author

Stiff, Andrew, Fornerod, Maarten, Kain, Bailee N., Nicolet, Deedra, Kelly, Benjamin J., Miller, Katherine E., Mrózek, Krzysztof, Boateng, Isaiah, Bollas, Audrey, Garfinkle, Elizabeth A. R., Momoh, Omolegho, Fasola, Foluke A., Olawumi, Hannah O., Mencia-Trinchant, Nuria, Kloppers, Jean F., van Marle, Anne-Cecilia, Hu, Eileen, Wijeratne, Saranga, Wheeler, Gregory, Walker, Christopher J., Buss, Jill, Heyrosa, Adrienne, Desai, Helee, Laganson, Andrea, Hamp, Ethan, Abu-Shihab, Yazan, Abaza, Hasan, Kronen, Parker, Sen, Sidharth, Johnstone, Megan E., Quinn, Kate, Wronowski, Ben, Hertlein, Erin, Miles, Linde A., Mims, Alice S., Oakes, Christopher C., Blachly, James S., Larkin, Karilyn T., Mundy-Bosse, Bethany, Carroll, Andrew J., Powell, Bayard L., Kolitz, Jonathan E., Stone, Richard M., Duarte, Cassandra, Abbott, Diana, Amaya, Maria L., Jordan, Craig T., Uy, Geoffrey L., Stock, Wendy, Archer, Kellie J., Paskett, Electra D., Guzman, Monica L., Levine, Ross L., Menghrajani, Kamal, Chakravarty, Debyani, Berger, Michael F., Bottomly, Daniel, McWeeney, Shannon K., Tyner, Jeffrey W., Byrd, John C., Salomonis, Nathan, Grimes, H. Leighton, Mardis, Elaine R., and Eisfeld, Ann-Kathrin

Published
2024
Full Text
View/download PDF

45. Impact of SGLT2 Inhibitors on Very Elderly Population with Heart Failure with Reduce Ejection Fraction: Real Life Data

Author

Jorge Balaguer Germán, Marcelino Cortés García, Carlos Rodríguez López, Jose María Romero Otero, Jose Antonio Esteban Chapel, Antonio José Bollas Becerra, Luis Nieto Roca, Mikel Taibo Urquía, Ana María Pello Lázaro, and José Tuñón Fernández

Subjects
HFrEF, elderly, SGLT2i, propensity score, Biology (General), QH301-705.5
Abstract

(1) Background: The validation of new lines of therapy for the elderly is required due to the progressive ageing of the world population and scarce evidence in elderly patients with HF with reduced ejection fraction (HFrEF). The purpose of our study is to analyze the effect of SGLT2 inhibitors (SGLT2i) in this subgroup of patients. (2) Methods: A single-center, real-world observational study was performed. We consecutively enrolled all patients aged ≥ 75 years diagnosed with HFrEF and for treatment with SGLT2i, and considered the theoretical indications. (3) Results: A total of 364 patients were recruited, with a mean age of 84.1 years. At inclusion, the mean LVEF was 29.8%. Median follow-up was 33 months, and there were 122 deaths. A total of 55 patients were under SGLT2i treatment. A multivariate Cox logistic regression test for all-cause mortality was performed, and only SGLT2i (HR 0.39 [0.19–0.82]) and glomerular filtration rate (HR 0.98 [0.98–0.99]) proved to be protective factors. In parallel, we conducted a propensity-score-matched analysis, where a significant reduction in all-cause mortality was associated with the use of SGLT2i treatment (HR 0.39, [0.16–0.97]). (4) Conclusions: Treatment with SGLT2i in elderly patients with HFrEF was associated with a lower rate of all-cause mortality. Our data show that SGLT2i therapy could improve prognosis in the elderly with HFrEF in a real-world study.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results